ADAM17 and neoplasm: To further evaluate the correlation between ADAM17 and the protumorigenic macrophage markers, we stained a triple-negative breast cancer cohort, including tumor tissue from 159 patients, for ADAM17 by immunohistochemistry (IHC) (Figure 1B).